[1] Dasch B, Kalies H, Feddersen B, Ruderer C, Hiddemann W, Bausewein C. Care of cancer patients at the end of life in a German university hospital: A retrospective observational study from 2014. PLoS One 2017;12:e0175124.
[2] Heikkilä R, Kaasa S. Chemotherapy in end-of-life care. Ann Oncol 2017;28:684–5.
[3] Earle CC, Park ER, Lai B, Weeks JC, Ayanian JZ, Block S. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol 2003;21:1133–8.
[4] Earle CC, Landrum MB, Souza JM, et al. Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue? J Clin Oncol 2008;26:3860-3866.
[5] Barbera L, Seow H, Sutradhar R, Chu A, Burge F, Fassbender K, et al. Quality Indicators of End-of-Life Care in Patients With Cancer: What Rate Is Right? J Oncol Pract 2015;11:e279–87.
[6] Kassam A, Sutradhar R, Widger K, et al. Predictors of and Trends in High-Intensity End-of-Life Care Among Children With Cancer: A Population-Based Study Using Health Services Data. J Clin Oncol 2017;35:236-242.
[7] Wang R, Zeidan AM, Halene S, et al. Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. J Clin Oncol 2017;35:3417-3424.
[8] Taylor JS, Rajan SS, Zhang N, et al. End-of-Life Racial and Ethnic Disparities Among Patients With Ovarian Cancer. J Clin Oncol 2017;35:1829-1835.
[9] Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, et al. American society of clinical oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol 2012;30:1715–24.
[10] Ho TH, Barbera L, Saskin R, Lu H, Neville BA, Earle CC. Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol 2011;29:1587–91.
[11] Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733–42.
[12] Whitney RL, Bell JF, Tancredi DJ, Romano PS, Bold RJ, Wun T, et al. Unplanned Hospitalization Among Individuals With Cancer in the Year After Diagnosis. J Oncol Pract 2019;15:e20–9.
[13] Mor V, Wagner TH, Levy C, Ersek M, Miller C, Gidwani-marszowski R, et al. Association of Expanded VA Hospice Care With Aggressive Care and Cost for Veterans With Advanced Lung Cancer. JAMA Oncol. 2019 Jun 1;5(6):810-816.
[14] Innos K, Oselin K, Laisaar T, Aareleid T. Patterns of survival and surgical treatment in lung cancer patients in Estonia by histologic type and stage, 1996–2016. Acta Oncol 2019:1–8.
[15] Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, et al. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncol 2015;1:778.
[16] Rochigneux P, Raoul JL, Beaussant Y, Aubry R, Goldwasser F, Tournigand C, et al. Use of chemotherapy near the end of life: what factors matter? Ann Oncol 2017;28:809–17.
[17] Bekelman JE, Halpern SD, Blankart CR, Bynum JP, Cohen J, Fowler R, et al. Comparison of Site of Death, Health Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in 7 Developed Countries. JAMA 2016;315:272.
[18] Fang P, Jagsi R, He W, Lei X, Campbell EG, Giordano SH, et al. Rising and Falling Trends in the Use of Chemotherapy and Targeted Therapy Near the End of Life in Older Patients With Cancer. J Clin Oncol 2019;37:1721–31.
[19] Wallington M, Saxon EB, Bomb M, Smittenaar R, Wickenden M, McPhail S, et al. 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. Lancet Oncol 2016;17:1203–16.
[20] Tai E, Guy GP, Dunbar A, Richardson LC. Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012. J Oncol Pract 2017;13:e552–61.
[21] Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015;33:3199–212.